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Objectives This study sought to assess the effectiveness of a novel percutaneous method to treat
left ventricular assist device (LVAD)–associated severe aortic insufﬁciency (AI) in a series of patients
determined to be poor reoperative candidates.
Background The increased use of continuous-ﬂow LVAD in advanced heart failure has led to
marked changes in the management of patients with this condition. However, secondary AI can be-
come a signiﬁcant complication.
Methods Five patients with continuous-ﬂow LVAD and severe post-LVAD AI underwent percutane-
ous transcatheter aortic valve closure from September to October 2011 at a single quaternary care
academic medical center. All patients had LVAD implanted as destination therapy. LVAD parameters,
hemodynamics, and echocardiographic measurements were obtained before and after aortic valve
closure.
Results All patients underwent successful closure with the Amplatzer cribriform device (AGA Medi-
cal, Plymouth, Minnesota) via a percutaneous transcatheter femoral approach with a signiﬁcant re-
duction of AI from severe to trivial. Cardiac hemodynamics improved, and the pulmonary capillary
wedge pressure was reduced in all patients. There was no change in mitral or tricuspid regurgita-
tion, LVAD power, or pulsatility index.
Conclusions Percutaneous transcatheter closure of the aortic valve effectively treats LVAD-associated AI
and reduces pulmonary capillary wedge pressure. This procedure should be considered to treat LVAD-
associated AI in patients who are poor candidates for repeat operation. Further data are needed to
assess long-term results. (J Am Coll Cardiol Intv 2013;6:84–9) © 2013 by the American College of
Cardiology Foundation
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85Left ventricular assist devices (LVAD) improve survival and
quality of life in patients with heart failure and are being
increasingly used as destination therapy. More than one-
third of all listed adult heart transplant candidates and 75%
of those initially listed as U.S. United Network for Organ
Sharing status 1 have undergone LVAD implantation since
1999 (1). However, development of de novo aortic insuffi-
ciency (AI) is a significant complication recognized with
long-term LVAD support, especially with increased use of
continuous-flow devices. Cowger et al. (2) recently reported
a 51% prevalence of moderate or severe AI after 18 months
of continuous-flow LVAD therapy with HeartMate II
(Thoratec, Pleasanton, California) devices. The develop-
ment of AI results in blood returning to the left ventricle via
a low-resistance circuit and leads to ineffective device
support, decreased device durability, and end organ mal-
perfusion. The development of AI in this population is
associated with increased morbidity and mortality after 1
year (3).
To avoid the development of LVAD-associated AI,
aortic valve (AV) closure during LVAD insertion has been
achieved using the Park stitch for suturing the AV leaflets
(4) or the sandwich plug technique, which employs felt
patches on either side of the AV (5). Unfortunately, surgical
closure to treat LVAD-associated AI is also often compli-
cated by AI recurrence resulting in a significant risk and is
associated with an operative mortality as high as 7% (6).
Many patients with LVAD and significant AI develop
severe decompensated heart failure and are not reoperative
candidates due to their clinical status. A less-invasive
approach using an open surgical transcatheter technique to
treat LVAD-associated AI was recently reported by Gro-
hmann et al. (7). We have also previously described a
percutaneous transcatheter method to reduce severe AI (8).
The aim of this study was to assess the effectiveness of a
novel percutaneous technique to treat LVAD-associated
severe AI and to assess its effectiveness using echocardiog-
raphy and hemodynamics in a series of patients determined
to be poor reoperative candidates.
Methods
Informed, written consent was obtained for data derived
from human subjects. After informed consent was obtained,
5 consecutive patients with continuous-flow LVAD (4
HeartMate II, 1 HeartWare device, Thoratec) and post-
LVAD severe AI at a single, quaternary care academic
medical center underwent the procedure in September and
October 2011. Cardiothoracic surgery and interventional
cardiology services had previously discussed the care of each
patient and jointly determined that their operative risk was
excessively high (operative mortality risk 75%) to recom-
mend surgical closure.Procedure. After standard placement of femoral arterial and
enous sheaths, a 7-F Swan-Ganz pulmonary artery cathe-
er (Edwards Lifesciences, Irvine, California) was used to
btain initial hemodynamic measurements. A 6-F multi-
urpose catheter was used to cross the aortic valve and then
xchanged for an 8-F, 80-cm, 45° TorqVue catheter (AGA
edical, Plymouth, Minnesota). Using transesophageal
chocardiography (TEE) guidance, the AV annulus was
easured. A 25-, 30-, or 35-mm Amplatzer Multi-
enestrated Septal Occluder—cribriform—device (AGA
edical, Plymouth, Minnesota) was selected so the size of
he device would match as closely as possible the annulus
ize. The selected device was advanced to the AV. The
evice was deployed under fluoroscopic and transesophageal
uidance across the AV. Closure of the AV and reduction of
I was confirmed by TEE. Patency of the coronary arteries
as subsequently established with coronary angiography
nd removal of the femoral sheaths was managed by manual
ompression.
Data collection and statistical analysis. Patient characteris-
ics, including demographics,
nd clinical and laboratory val-
es were obtained from the elec-
ronic medical record (Table 1).
etermination of anatomically
ormal AV was made with
ransthoracic echocardiography
TTE) performed within 1 week
f LVAD implantation. LVAD
arameters were obtained before
V closure and on days 1 and 3
fter AV closure (Table 2). He-
odynamics were measured im-
ediately before and 5 min after
V closure (Table 3). Intraprocedural TEE and TTE
cquired 12 days before and 6 days after the procedure were
sed to assess the severity of aortic insufficiency with
tandard guideline criteria. The Wilcoxon signed-rank test
or matched pairs was performed for pre- and post-AV
losure data. A p value 0.05 was considered statistically
ignificant. Statistical analysis was performed using SPSS
ersion 19 (IBM, Armonk, New York). Results are reported
s median (range) unless otherwise specified.
esults
All 5 patients underwent successful placement of the Am-
platzer device (Figs. 1 and 2). The average age was 52 years,
4 were men, and 40% had an LVAD placed for ischemic
cardiomyopathy. The median time of LVAD support before
AV closure was 1.0 years (0.4 to 2.1 years). Relevant clinical
and laboratory characteristics are reported in Table 1. There
was near-complete resolution of the aortic insufficiency (AI)
Abbreviations
and Acronyms
AI  aortic insufficiency
AV  aortic valve(s)
LVAD  left ventricular
assist device(s)
PCWP  pulmonary capillary
wedge pressure
TEE  transesophageal
echocardiography
TTE  transthoracic
echocardiographyin all patients with TEE (Fig. 1, Online Video 1). There
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86were no immediate complications in any of the procedures.
After 4 days, 1 device was found to have embolized to the
aortic arch in 1 patient and was successfully retrieved
percutaneously. At 30 days, 2 of the patients were alive and
TTE demonstrated a static device and no further AI. One
patient developed severe right heart failure, and the family
withdrew care at post-procedure day 12 after he developed
renal failure. The remaining patient died on post-procedure
day 18 from sepsis. In both of these patients, TTE (ob-
tained at least 10 days after the index procedure) revealed
the device in position and no further AI.
LVAD parameters. LVAD parameters, including pump
ow, speed, pulsatility index, and pump power pre-, 1 day
ost-, 3 days post-AV closure are shown in Table 2. There
as a trend toward increased pump flow (p 0.083) on day
but this trend was not maintained on day 3.
Echocardiographic data. TTE showed improvement of AI
rom severe to mild or absent (p  0.038) after AV closure
n all patients confirming the results noted with intrapro-
edural TEE (Fig. 1). Mild-to-moderate mitral regurgita-
ion and severe tricuspid regurgitation were also observed
re-AV closure in all patients. There was no post-
rocedural change in the severity of either mitral or tricus-
id regurgitation in any of the patients.
Table 1. Patient Characteristics
Men 4
Age, yrs 54.5 (37.1–69.8)
LVAD type, continuous 5
Body mass index, kg/m2 32.4 (27.2–44.0)
Etiology of heart failure, ischemic 2
Prior myocardial infarction 3
Prior coronary artery bypass 2
History of atrial ﬁbrillation 2
Chronic kidney disease 2
Diabetes mellitus 2
Hyperlipidemia 4
Prior or current tobacco use 4
Hemoglobin, g/dl 10.7 (7.9–13.4)
Sodium, mmol/l 124 (120–129)
Estimated glomerular ﬁltration rate, ml/min/1.73 m2 53 (27–87)
Values for continuous variables are reported as median (range).
LVAD left ventricular assist device(s).
Table 2. Effect of AV Closure on LVAD Parameters in LVAD-Associated Sev
Pre-AV Closure Post-AV Closure (
Pump ﬂow. l/min 6 (4.0–7.0) 6 (5.0–8.0)
Speed, rev/min 9,590 (3,220–10,400) 9,600 (3,300–10,
Pulsatility index 3.5 (3.0–4.0) 3.0 (3.0)
Pump power, W 7.5 (7.0–8.0) 7.5 (6.0–8.0)
Values are median (range). The p values are for matched differences between pre- and post-AV closAV aortic valve; LVAD left ventricular assist device(s).Hemodynamics. Right ventricular systolic pressure, mean
pulmonary artery pressure, pulmonary capillary wedge pres-
sure (PCWP), and left ventricular end-diastolic pressure all
decreased significantly post-Amplatzer device implantation
(Table 3, Fig. 3) without a change in the right atrial
pressure. Pulmonary artery saturation increased signifi-
cantly, and there was a trend toward an increase in cardiac
output with the procedure, with 1 patient having unchanged
cardiac output and the rest having increased values. Notably,
1 patient’s cardiac output increased dramatically from 2.4 to
3.3 l/min after AV closure.
Discussion
We present a series of patients with LVAD-associated
severe AI who were effectively treated with a percutaneous
transcatheter technique. Our study shows that LVAD-
associated severe AI can be successfully and safely treated
with our approach to AV closure using an Amplatzer
Multi-Fenestrated Septal Occluder—cribriform—device in
patients who are poor reoperative candidates. We also
observed significant improvement in patients’ hemodynam-
ics following the procedure. There was 1 device emboliza-
tion that occurred in a patient with a prosthetic mitral valve,
in whom the prosthetic strut extended into the left ventric-
I
p Value Post-AV Closure (Day 3) p Value
0.083 7 (6.0–9.0) 0.109
0.068 9,600 (3,300–11,590) 0.068
0.157 3.0 (2.0–4.0) 0.317
1.00 7.5 (7.0–8.0) 0.414
Table 3. Effect of AV Closure on Hemodynamics in LVAD-Associated
Severe AI
Pre-AV
Closure
Post-AV
Closure
p
Value
Right atrial pressure, mm Hg 31 (26–37) 28 (21–33) 0.102
Right ventricular systolic pressure, mm Hg 64 (58–72) 53 (51–61) 0.043
Mean pulmonary artery pressure, mm Hg 65 (58–71) 54 (50–60) 0.043
Pulmonary artery saturation, % 33 (27–41) 39 (31–49) 0.043
Pulmonary capillary wedge pressure, mm Hg 30 (28–37) 24 (22–33) 0.042
Left ventricular end-diastolic pressure, mm Hg 34 (28–41) 25 (22–35) 0.042
Cardiac output, Fick, l/min 2.6 (2.1–3.3) 3.1 (2.5–3.6) 0.109
Cardiac index, l/min/m2 1.5 (1.3–2.1) 1.8 (1.6–2.3) 0.109
Values are median (range). The p values are for matched differences between pre- and post-AV
closure.
AI aortic insufficiency; other abbreviations as in Tables 1 and 2.ere A
Day 1)
800)
ure.
of AI (C) (Online Video 1).
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87ular outflow tract may have prevented adequate seating of
the device.
The transcatheter technique as a preferred approach to
addressing LVAD-associated AI is receiving increased at-
tention because it is less invasive than is open surgical repair.
Grohmann et al. (7) used a surgical transcatheter technique
with an Amplatzer ventricular septal defect plug, and
Santini et al. (9) recently used a CoreValve (Medtronic,
Minneapolis, Minnesota) to treat LVAD-associated AI.
Additionally, although not in a patient with an LVAD,
Riede et al. (10) reported successful closure of the AV with
an atrial septal occluder in an infant with hypoplastic left
heart syndrome. Our technique is the first percutaneous
method to our knowledge reported in a series of patients.
Figure 2. Placement of the Amplatzer Cribriform Septal Occluder Device
at the AV With Fluoroscopy
AV  aortic valve.
Figure 3. Pre- and Post-PCWP for Each Patient
Pulmonary capillary wedge pressure (PCWP) decreases with AV closure in
left ventricular assist device–associated severe AI (p  0.038).Figure 1. TEE During Procedure Shows Improvement of AI
Transesophageal echocardiography (TEE) views of left ventricular assist
device–associated severe aortic insufﬁciency (AI) (A), placement of
Amplatzer cribriform Septal Occluder device (B), and subsequent resolutionAbbreviations as in Figures 1 and 2.
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88Development of LVAD-associated AI. The increasing use of
continuous-flow LVAD for the treatment of advanced
heart failure patients and the increased life expectancy of
patients who receive LVAD has made the development
of severe AI a significant morbidity and mortality risk in
this patient population (3). The exact etiology is un-
known and likely multifactorial. Mobility and integrity of
the valve may be compromised over time due to the
LVAD’s redirection of blood flow, especially in patients
with ventricles too weak to generate enough intracham-
ber pressure to open the AV (2,11). Intermittent opening
of the AV has been demonstrated to result in commis-
sural fusion and development of myxomatous granulation
tissue on the coronary cusps, and fused valves may
degenerate when exposed to high-velocity flow from the
aortic cannula (12). In addition to the ability of pulsatile-
flow LVAD to allow physiological opening of the AV,
aortic regurgitation has been reported to be increased
more in continuous-flow than in pulsatile-flow devices
and is likely secondary to differences in aortic blood flow
patterns and smaller outflow cannulas (2,13–15).
Beneﬁts and considerations of percutaneous AV closure.
OPTIMIZING LVAD FUNCTION. The underlying challenge of
I occurrence in patients with LVAD support is that a
ow-resistance continuous circuit is created by which the
egurgitant blood returns from the LVAD outflow cannula
irectly back into the inflow cannula in the left ventricle. As
result, net systemic flow via the higher resistance arterial
ircuit will decrease even as device readings indicate higher
ump flows. Therefore, despite efforts to improve systemic
erfusion by increasing power and flow, effective output will
rogressively diminish as AI worsens. Closing this low-
esistance circuit with the Amplatzer occluder reduces the
emands on the LVAD, improves systemic flow, and increases
he LVAD’s durability and longevity. Although our results do
ot show a significant change in pump flow before and after
V closure, pre-closure flows are artificially elevated because of
VAD inefficiency in the setting of AI (2,16).
IMPROVEMENT OF DIASTOLIC FILLING PRESSURES. We
ave shown that by treating LVAD-associated AI, several
emodynamic parameters, including PCWP and left ven-
ricular end-diastolic pressure, are significantly improved.
CWP has been shown to be an independent predictor of
urvival in patients with an ejection fraction20% from either
schemic or nonischemic cardiomyopathy (17). There is also
vidence supporting that an elevated PCWP contributes to
ight ventricular dysfunction directly by increasing net right
entricular afterload (18). Elevated PCWP also correlates with
ymptoms of dyspnea, orthopnea, and paroxysmal nocturnal
yspnea. Though not statistically significant in this study, and
ikely confounded by significant tricuspid regurgitation and
ight ventricular failure, the observed decrease in right atrial
ressure in all patients suggests that the right ventricle is
nloaded in addition to the left ventricle.Study limitations. The results from this study are limited by
its nonrandomized, small sample size. Adjustments for
sample bias were made by assuming a nonparametric pop-
ulation in the statistical analysis. Another limitation of our
study is the lack of long-term follow-up. The long-term
implications of AV closure by any method in patients with
LVAD are unclear, and device malfunction in this setting
could result in immediate hemodynamic collapse and death.
Conclusions
Percutaneous transcatheter AV closure appears to be a safe
and effective method to treat severe aortic insufficiency in
patients with LVAD, a population often too sick to undergo
reoperation for treatment. Although our results are encour-
aging, the technique needs to be studied in a larger cohort
for longer-term follow-up.
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